NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $36.20.
A number of analysts have recently issued reports on NAMS shares. Royal Bank of Canada reiterated an "outperform" rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Piper Sandler reaffirmed an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th.
View Our Latest Research Report on NAMS
In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60. Following the sale, the insider now directly owns 11,812,033 shares of the company's stock, valued at approximately $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. Insiders have sold 353,542 shares of company stock worth $8,599,328 over the last quarter. 19.50% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise acquired a new position in shares of NewAmsterdam Pharma during the second quarter valued at $38,000. Quarry LP boosted its stake in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after purchasing an additional 6,247 shares during the period. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Bellevue Group AG acquired a new stake in shares of NewAmsterdam Pharma in the third quarter valued at approximately $128,000. Finally, XTX Topco Ltd bought a new stake in shares of NewAmsterdam Pharma during the third quarter valued at approximately $187,000. 89.89% of the stock is currently owned by institutional investors.
Shares of NASDAQ:NAMS opened at $25.95 on Thursday. The business's 50-day simple moving average is $21.72 and its 200 day simple moving average is $19.09. NewAmsterdam Pharma has a one year low of $10.50 and a one year high of $27.29.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.